VIVUS, Inc. Comments on Sam Colin's Questionable Claims
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MOUNTAIN VIEW, Calif., June 25, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the "Company"), a pharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced that it believes First Manhattan Co.'s ("FMC") recent letter to stockholders contains several highly questionable claims and would like to set the record straight.
Help employers find you! Check out all the jobs and post your resume.
MOUNTAIN VIEW, Calif., June 25, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the "Company"), a pharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced that it believes First Manhattan Co.'s ("FMC") recent letter to stockholders contains several highly questionable claims and would like to set the record straight.
Help employers find you! Check out all the jobs and post your resume.